Dasatinib for the treatment of Philadelphia chromosome-positive leukemias

Bibliography

• Sant M, Allemani C, Tereanu C, Incidence of hematologic malignancies in Europe by morphologic subtype: results of the HAEMACARE project. Blood 2010;116:3724-34
   PubMed Web of Science ®Google Scholar
• Quintas-Cardama A, Cortes J. Molecular biology of bcr-abl1-positive chronic myeloid leukemia. Blood 2009;113:1619-30
   PubMed Web of Science ®Google Scholar
• Sawyers CL. Chronic myeloid leukemia. N Engl J Med 1999;340:1330-40
   PubMed Web of Science ®Google Scholar
• Moorman AV, Harrison CJ, Buck GA, Karyotype is an independent prognostic factor in adult acute lymphoblastic leukemia (ALL): analysis of cytogenetic data from patients treated on the Medical Research Council (MRC) UKALLXII/Eastern Cooperative Oncology Group (ECOG) 2993 trial. Blood 2007;109:3189-97
   PubMed Web of Science ®Google Scholar
• Deininger M, O'Brien SG, Guilhot F, International randomized study of interferon vs STI571 (IRIS) 8-year follow up: sustained survival and low risk for progression or events in patients with newly diagnosed Chronic Myeloid Leukemia in Chronic Phase (CML-CP) treated with imatinib [abstract]. Blood 2009;114:abstract 1126
   Web of Science ®Google Scholar
• Hochhaus A, Baccarani M, Deininger M, Dasatinib induces durable cytogenetic responses in patients with chronic myelogenous leukemia in chronic phase with resistance or intolerance to imatinib. Leukemia 2008;22:1200-6
   PubMed Web of Science ®Google Scholar
• Kantarjian H, Shah NP, Hochhaus A, Dasatinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med 2010;362:2260-70
   PubMed Web of Science ®Google Scholar
• Baccarani M, Cortes J, Pane F, Chronic myeloid leukemia: an update of concepts and management recommendations of European LeukemiaNet. J Clin Oncol 2009;27:6041-51
   PubMed Web of Science ®Google Scholar
• Druker BJ, Guilhot F, O'Brien SG, Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. N Engl J Med 2006;355:2408-17
   PubMed Web of Science ®Google Scholar
• Lahaye T, Riehm B, Berger U, Response and resistance in 300 patients with BCR-ABL-positive leukemias treated with imatinib in a single center: a 4.5-year follow-up. Cancer 2005;103:1659-69
   PubMed Web of Science ®Google Scholar
• Gorre ME, Mohammed M, Ellwood K, Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification. Science 2001;293:876-80
   PubMed Web of Science ®Google Scholar
• Shah NP, Nicoll JM, Nagar B, Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia. Cancer Cell 2002;2:117-25
   PubMed Web of Science ®Google Scholar
• Soverini S, Martinelli G, Rosti G, ABL mutations in late chronic phase chronic myeloid leukemia patients with up-front cytogenetic resistance to imatinib are associated with a greater likelihood of progression to blast crisis and shorter survival: a study by the GIMEMA Working Party on Chronic Myeloid Leukemia. J Clin Oncol 2005;23:4100-9
   PubMed Web of Science ®Google Scholar
• Jabbour E, Kantarjian H, Jones D, Frequency and clinical significance of BCR-ABL mutations in patients with chronic myeloid leukemia treated with imatinib mesylate. Leukemia 2006;20:1767-73
   PubMed Web of Science ®Google Scholar
• Jones D, Luthra R, Cortes J, BCR-ABL fusion transcript types and levels and their interaction with secondary genetic changes in determining the phenotype of Philadelphia chromosome-positive leukemias. Blood 2008;112:5190-2
   PubMedGoogle Scholar
• O'Hare T, Walters DK, Stoffregen EP, In vitro activity of Bcr-Abl inhibitors AMN107 and BMS-354825 against clinically relevant imatinib-resistant Abl kinase domain mutants. Cancer Res 2005;65:4500-5
   PubMed Web of Science ®Google Scholar
• Sherbenou DW, Hantschel O, Kaupe I, BCR-ABL SH3-SH2 domain mutations in chronic myeloid leukemia patients on imatinib. Blood 2010;116:3278-85
   PubMed Web of Science ®Google Scholar
• Donato NJ, Wu JY, Stapley J, BCR-ABL independence and LYN kinase overexpression in chronic myelogenous leukemia cells selected for resistance to STI571. Blood 2003;101:690-8
   PubMed Web of Science ®Google Scholar
• Ito T, Tanaka H, Kimura A. Establishment and characterization of a novel imatinib-sensitive chronic myeloid leukemia cell line MYL, and an imatinib-resistant subline MYL-R showing overexpression of Lyn. Eur J Haematol 2007;78:417-31
   Google Scholar
• Wu J, Meng F, Kong LY, Association between imatinib-resistant BCR-ABL mutation-negative leukemia and persistent activation of LYN kinase. J Natl Cancer Inst 2008;100:926-39
   PubMed Web of Science ®Google Scholar
• Pene-Dumitrescu T, Smithgall TE. Expression of a Src family kinase in chronic myelogenous leukemia cells induces resistance to imatinib in a kinase-dependent manner. J Biol Chem 2010;285:21446-57
   PubMed Web of Science ®Google Scholar
• Wu J, Meng F, Lu H, Lyn regulates BCR-ABL and Gab2 tyrosine phosphorylation and c-Cbl protein stability in imatinib-resistant chronic myelogenous leukemia cells. Blood 2008;111:3821-9
   PubMed Web of Science ®Google Scholar
• Hu Y, Liu Y, Pelletier S, Requirement of Src kinases Lyn, Hck and Fgr for BCR-ABL1-induced B-lymphoblastic leukemia but not chronic myeloid leukemia. Nat Genet 2004;36:453-61
   PubMed Web of Science ®Google Scholar
• Lombardo LJ, Lee FY, Chen P, Discovery of N-(2-chloro-6-methyl- phenyl)-2-(6-(4-(2-hydroxyethyl)- piperazin-1-yl)-2-methylpyrimidin-4- ylamino)thiazole-5-carboxamide (BMS-354825), a dual Src/Abl kinase inhibitor with potent antitumor activity in preclinical assays. J Med Chem 2004;47:6658-61
   PubMed Web of Science ®Google Scholar
• Wityak J, Das J, Moquin RV, Discovery and initial SAR of 2-amino-5-carboxamidothiazoles as inhibitors of the Src-family kinase p56(Lck). Bioorg Med Chem Lett 2003;13:4007-10
   PubMedGoogle Scholar
• Tokarski JS, Newitt JA, Chang CY, The structure of Dasatinib (BMS-354825) bound to activated ABL kinase domain elucidates its inhibitory activity against imatinib-resistant ABL mutants. Cancer Res 2006;66:5790-7
   PubMed Web of Science ®Google Scholar
• Nagar B, Bornmann WG, Pellicena P, Crystal structures of the kinase domain of c-Abl in complex with the small molecule inhibitors PD173955 and imatinib (STI-571). Cancer Res 2002;62:4236-43
   PubMed Web of Science ®Google Scholar
• Bradeen HA, Eide CA, O'Hare T, Comparison of imatinib mesylate, dasatinib (BMS-354825), and nilotinib (AMN107) in an N-ethyl-N-nitrosourea (ENU)-based mutagenesis screen: high efficacy of drug combinations. Blood 2006;108:2332-8
   PubMed Web of Science ®Google Scholar
• Soverini S, Martinelli G, Colarossi S, Presence or the emergence of a F317L BCR-ABL mutation may be associated with resistance to dasatinib in Philadelphia chromosome-positive leukemia. J Clin Oncol 2006;24:e51-2
   PubMedGoogle Scholar
• Jabbour E, Kantarjian HM, Jones D, Characteristics and outcome of chronic myeloid leukemia patients with F317L BCR-ABL kinase domain mutation after therapy with tyrosine kinase inhibitors. Blood 2008;112:4839-42
   PubMed Web of Science ®Google Scholar
• Shah NP, Skaggs BJ, Branford S, Sequential ABL kinase inhibitor therapy selects for compound drug-resistant BCR-ABL mutations with altered oncogenic potency. J Clin Invest 2007;117:2562-9
   PubMed Web of Science ®Google Scholar
• Shah NP, Tran C, Lee FY, Overriding imatinib resistance with a novel ABL kinase inhibitor. Science 2004;305:399-401
   PubMed Web of Science ®Google Scholar
• Christopher LJ, Cui D, Wu C, Metabolism and disposition of dasatinib after oral administration to humans. Drug Metab Dispos 2008;36:1357-64
   PubMed Web of Science ®Google Scholar
• Bristol Myers-Squibb. Sprycel prescribing information. Available from: http://packageinserts.bms.com/pi/pi_sprycel.pdf [Accessed 15 February 2012]
   Google Scholar
• Hiwase DK, Saunders V, Hewett D, Dasatinib cellular uptake and efflux in chronic myeloid leukemia cells: therapeutic implications. Clin Cancer Res 2008;14:3881-8
   PubMed Web of Science ®Google Scholar
• Giannoudis A, Davies A, Lucas CM, Effective dasatinib uptake may occur without human organic cation transporter 1 (hOCT1): implications for the treatment of imatinib-resistant chronic myeloid leukemia. Blood 2008;112:3348-54
   PubMed Web of Science ®Google Scholar
• Eley T, Luo FR, Agrawal S, Phase I study of the effect of gastric acid pH modulators on the bioavailability of oral dasatinib in healthy subjects. J Clin Pharmacol 2009;49:700-9
   PubMed Web of Science ®Google Scholar
• Takahashi N, Miura M, Niioka T, Influence of H2-receptor antagonists and proton pump inhibitors on dasatinib pharmacokinetics in Japanese leukemia patients. Cancer Chemother Pharmacol 2011;70(2):351-2
   Google Scholar
• Porkka K, Koskenvesa P, Lundan T, Dasatinib crosses the blood-brain barrier and is an efficient therapy for central nervous system Philadelphia chromosome-positive leukemia. Blood 2008;112:1005-12
   PubMed Web of Science ®Google Scholar
• Talpaz M, Shah NP, Kantarjian H, Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias. N Engl J Med 2006;354:2531-41
   PubMed Web of Science ®Google Scholar
• Hochhaus A, Kantarjian HM, Baccarani M, Dasatinib induces notable hematologic and cytogenetic responses in chronic-phase chronic myeloid leukemia after failure of imatinib therapy. Blood 2007;109:2303-9
   PubMed Web of Science ®Google Scholar
• Guilhot F, Apperley J, Kim DW, Dasatinib induces significant hematologic and cytogenetic responses in patients with imatinib-resistant or -intolerant chronic myeloid leukemia in accelerated phase. Blood 2007;109:4143-50
   PubMed Web of Science ®Google Scholar
• Apperley JF, Cortes JE, Kim DW, Dasatinib in the treatment of chronic myeloid leukemia in accelerated phase after imatinib failure: the START a trial. J Clin Oncol 2009;27:3472-9
   PubMed Web of Science ®Google Scholar
• Cortes J, Rousselot P, Kim DW, Dasatinib induces complete hematologic and cytogenetic responses in patients with imatinib-resistant or -intolerant chronic myeloid leukemia in blast crisis. Blood 2007;109:3207-13
   PubMed Web of Science ®Google Scholar
• Cortes J, Kim DW, Raffoux E, Efficacy and safety of dasatinib in imatinib-resistant or -intolerant patients with chronic myeloid leukemia in blast phase. Leukemia 2008;22:2176-83
   PubMed Web of Science ®Google Scholar
• Kantarjian H, Pasquini R, Hamerschlak N, Dasatinib or high-dose imatinib for chronic-phase chronic myeloid leukemia after failure of first-line imatinib: a randomized phase 2 trial. Blood 2007;109:5143-50
   PubMed Web of Science ®Google Scholar
• Kantarjian H, Pasquini R, Levy V, Dasatinib or high-dose imatinib for chronic-phase chronic myeloid leukemia resistant to imatinib at a dose of 400 to 600 milligrams daily: two-year follow-up of a randomized phase 2 study (START-R). Cancer 2009;115:4136-47
   PubMed Web of Science ®Google Scholar
• Fava C, Kantarjian HM, Jabbour E, Failure to achieve a complete hematologic response at the time of a major cytogenetic response with second-generation tyrosine kinase inhibitors is associated with a poor prognosis among patients with chronic myeloid leukemia in accelerated or blast phase. Blood 2009;113:5058-63
   PubMed Web of Science ®Google Scholar
• Shah NP, Kantarjian HM, Kim DW, Intermittent target inhibition with dasatinib 100 mg once daily preserves efficacy and improves tolerability in imatinib-resistant and -intolerant chronic-phase chronic myeloid leukemia. J Clin Oncol 2008;26:3204-12
   PubMed Web of Science ®Google Scholar
• Shah NP, Kim DW, Kantarjian H, Potent, transient inhibition of BCR-ABL with dasatinib 100 mg daily achieves rapid and durable cytogenetic responses and high transformation-free survival rates in chronic phase chronic myeloid leukemia patients with resistance, suboptimal response or intolerance to imatinib. Haematologica 2010;95:232-40
   PubMed Web of Science ®Google Scholar
• Shah NP, Kasap C, Weier C, Transient potent BCR-ABL inhibition is sufficient to commit chronic myeloid leukemia cells irreversibly to apoptosis. Cancer Cell 2008;14:485-93
   PubMed Web of Science ®Google Scholar
• Nicaise C, Wang X, Roy A, Dasatinib pharmacokinetics and exposure-response (E-R): relationships to efficacy and safety in patients with chronic myelogeneous leukemia in chronic phase (CML-CP) [abstract]. Haematologica 2008;93(Suppl 1):abstract 0559
   Google Scholar
• Kantarjian H, Cortes J, Kim DW, Phase 3 study of dasatinib 140 mg once daily versus 70 mg twice daily in patients with chronic myeloid leukemia in accelerated phase resistant or intolerant to imatinib: 15-month median follow-up. Blood 2009;113:6322-9
   PubMed Web of Science ®Google Scholar
• Saglio G, Hochhaus A, Goh YT, Dasatinib in imatinib-resistant or imatinib-intolerant chronic myeloid leukemia in blast phase after 2 years of follow-up in a phase 3 study: efficacy and tolerability of 140 milligrams once daily and 70 milligrams twice daily. Cancer 2010;116:3852-61
   PubMed Web of Science ®Google Scholar
• Lilly MB, Ottmann OG, Shah NP, Dasatinib 140 mg once daily versus 70 mg twice daily in patients with Ph-positive acute lymphoblastic leukemia who failed imatinib: results from a phase 3 study. Am J Hematol 2010;85:164-70
   PubMed Web of Science ®Google Scholar
• Muller MC, Cortes JE, Kim DW, Dasatinib treatment of chronic-phase chronic myeloid leukemia: analysis of responses according to preexisting BCR-ABL mutations. Blood 2009;114:4944-53
   PubMed Web of Science ®Google Scholar
• Hughes T, Saglio G, Branford S, Impact of baseline BCR-ABL mutations on response to nilotinib in patients with chronic myeloid leukemia in chronic phase. J Clin Oncol 2009;27:4204-10
   PubMed Web of Science ®Google Scholar
• Cortes JE, Jones D, O'Brien S, Results of dasatinib therapy in patients with early chronic-phase chronic myeloid leukemia. J Clin Oncol 2010;28:398-404
   PubMed Web of Science ®Google Scholar
• Pemmaraju N, Kantarjian HM, Luthra R, Results of a phase II trial of dasatinib as frontline therapy for Chronic Myeloid Leukemia (CML) in Chronic Phase (CP) [abstract]. Blood 2011;118:abstract 1700
   Google Scholar
• Kantarjian HM, Shah NP, Cortes JE, Dasatinib or imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: 2-year follow-up from a randomized phase 3 trial (DASISION). Blood 2012;119:1123-9
   PubMed Web of Science ®Google Scholar
• Radich JP, Kopecky KJ, Kamel-Reid S, A Randomized phase II trial of dasatinib 100 mg vs imatinib 400 mg in newly diagnosed Chronic Myeloid Leukemia In Chronic Phase (CML-CP): the S0325 intergroup trial [abstract]. Blood 2010;116:abstract LBA-6
   Google Scholar
• Porkka K, Simonsson B, Dombret H, Efficacy of dasatinib in patients with philadelphia-chromosome-positive acute lymphoblastic leukemia who are resistant or intolerant to imatinib: 2-year follow-up data from START-L (CA180-015) [abstract]. Blood 2007;110:abstract 2810
   Google Scholar
• Foa R, Vitale A, Vignetti M, Dasatinib as first-line treatment for adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia. Blood 2011;118:6521-8
   PubMed Web of Science ®Google Scholar
• Ravandi F, O'Brien S, Thomas D, First report of phase 2 study of dasatinib with hyper-CVAD for the frontline treatment of patients with Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia. Blood 2010;116:2070-7
   PubMed Web of Science ®Google Scholar
• Rousselot P, Cayuela JM, Hayette S, Dasatinib (Sprycel(R)) and low intensity chemotherapy for first-line treatment in elderly patients with de novo Philadelphia Positive ALL (EWALL-PH-01): kinetic of response, resistance and prognostic significance [abstract]. Blood 2010;116:abstract 172
   Google Scholar
• Quintas-Cardama A, De Souza Santos FP, Kantarjian H, Dynamics and management of cytopenias associated with dasatinib therapy in patients with chronic myeloid leukemia in chronic phase after imatinib failure. Cancer 2009;115:3935-43
   PubMed Web of Science ®Google Scholar
• Quintas-Cardama A, Kantarjian H, O'Brien S, Pleural effusion in patients with chronic myelogenous leukemia treated with dasatinib after imatinib failure. J Clin Oncol 2007;25:3908-14
   PubMed Web of Science ®Google Scholar
• Lindahl P, Johansson BR, Leveen P, Pericyte loss and microaneurysm formation in PDGF-B-deficient mice. Science 1997;277:242-5
   PubMed Web of Science ®Google Scholar
• Mustjoki S, Ekblom M, Arstila TP, Clonal expansion of T/NK-cells during tyrosine kinase inhibitor dasatinib therapy. Leukemia 2009;23:1398-405
   PubMed Web of Science ®Google Scholar
• Kreutzman A, Juvonen V, Kairisto V, Mono/oligoclonal T and NK cells are common in chronic myeloid leukemia patients at diagnosis and expand during dasatinib therapy. Blood 2010;116:772-82
   PubMed Web of Science ®Google Scholar
• Powers JJ, Dubovsky JA, Epling-Burnette PK, A molecular and functional analysis of large granular lymphocyte expansions in patients with chronic myelogenous leukemia treated with tyrosine kinase inhibitors. Leuk Lymphoma 2011;52:668-79
   PubMed Web of Science ®Google Scholar
• Lee SJ, Jung CW, Kim DY, Retrospective multicenter study on the development of peripheral lymphocytosis following second-line dasatinib therapy for chronic myeloid leukemia. Am J Hematol 2011;86:346-50
   Google Scholar
• Quintas-Cardama A, Kantarjian H, Ravandi F, Bleeding diathesis in patients with chronic myelogenous leukemia receiving dasatinib therapy. Cancer 2009;115:2482-90
   PubMed Web of Science ®Google Scholar
• Quintas-Cardama A, Han X, Kantarjian H, Tyrosine kinase inhibitor-induced platelet dysfunction in patients with chronic myeloid leukemia. Blood 2009;114:261-3
   PubMed Web of Science ®Google Scholar
• Gratacap MP, Martin V, Valera MC, The new tyrosine-kinase inhibitor and anticancer drug dasatinib reversibly affects platelet activation in vitro and in vivo. Blood 2009;114:1884-92
   PubMed Web of Science ®Google Scholar
• Orlandi EM, Rocca B, Pazzano AS, Reversible pulmonary arterial hypertension likely related to long-term, low-dose dasatinib treatment for chronic myeloid leukaemia. Leuk Res 2012;36:e4-6
   Google Scholar
• Dumitrescu D, Seck C, ten Freyhaus H, Fully reversible pulmonary arterial hypertension associated with dasatinib treatment for chronic myeloid leukaemia. Eur Respir J 2011;38:218-20
   PubMed Web of Science ®Google Scholar
• Hennigs JK, Keller G, Baumann HJ, Multi tyrosine kinase inhibitor dasatinib as novel cause of severe pre-capillary pulmonary hypertension? BMC Pulm Med 2011;11:30
   PubMedGoogle Scholar
• Mattei D, Feola M, Orzan F, Reversible dasatinib-induced pulmonary arterial hypertension and right ventricle failure in a previously allografted CML patient. Bone Marrow Transplant 2009;43:967-8
   PubMed Web of Science ®Google Scholar
• Rasheed W, Flaim B, Seymour JF. Reversible severe pulmonary hypertension secondary to dasatinib in a patient with chronic myeloid leukemia. Leuk Res 2009;33:861-4
   PubMed Web of Science ®Google Scholar
• Jabbour E, Kantarjian HM, O'Brien S, Front-line therapy with second-generation tyrosine kinase inhibitors in patients with early chronic phase chronic myeloid leukemia: what is the optimal response? J Clin Oncol 2011;29:4260-5
   PubMed Web of Science ®Google Scholar
• Copland M, Hamilton A, Elrick LJ, Dasatinib (BMS-354825) targets an earlier progenitor population than imatinib in primary CML but does not eliminate the quiescent fraction. Blood 2006;107:4532-9
   PubMed Web of Science ®Google Scholar